NTLA - Intellia Therapeutics to Present Updated Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis and Hold Conference Call to Discuss Third Quarter 2023 Earnings in November | Benzinga
- New interim NTLA-2001 clinical data to be presented at the 4th International ATTR Amyloidosis Meeting on November 2; data to include safety and both absolute and percent change in serum TTR reduction from cardiomyopathy and polyneuropathy arms of the study
- Intellia management to discuss latest NTLA-2001 data and share additional information about the upcoming Phase 3 study design at Q3 earnings webcast on November 9 at 8 a.m. ET
CAMBRIDGE, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced two upcoming events in November.
NTLA-2001 Interim Clinical Data Update
Intellia will present updated data from the ongoing NTLA-2001 Phase 1 study for the treatment of transthyretin (ATTR) amyloidosis being presented at the 4th International ATTR Amyloidosis Meeting, taking place November 2 – 3 in Madrid, Spain.
- Presentation Details:
- Title: "Enabling the Development of Serum TTR as a Biomarker for Treatment of ATTR Amyloidosis"
- Date and Time: Thursday, November 2, 2023, from 11:30 a.m. – 1:00 p.m. CET
- Session: Latest Data for Patients' Diagnosis in a Changing World
- Presenter: Dr. Julian Gillmore, M.D, Ph.D., FRCP, FRCPath, Professor of Medicine, National Amyloidosis Centre, UCL Division of Medicine, Royal Free Hospital, U.K., the trial's U.K. national coordinating investigator
Third Quarter 2023 Earnings
Intellia will host a webcast to discuss its third quarter 2023 financial results and operational highlights on November 9, 2023, at 8 ...